half-hour program is part of the "Shape of Things to
Come" series and examines how a drug is brought from
the idea stage to the market place. A panel of experts explore
the theory, economics and politics involved getting a product
approved. The discussion will also address the years of
research, the clinical trials, lobbying, pricing, competition,
and marketing that take place throughout the process. The
panel will then examine how these elements impact the delivery
and costs of these medications to the citizens of New Jersey.
Kenneth Moch |
Dr. Neal Masia |
Dr. Richard Stefanacci
Kenneth Moch - President and CEO of Alteon
and the Chairman of the Biotechnology Council of New Jersey.
Dr. Richard Stefanacci - Executive Director
of the Health Policy Institute at the University of the Sciences in Philadelphia
and a practicing physician.
Sy Larson – Coordinator of the Prescription
Drug Task Force for AARP of New Jersey.
Dr. Neal Masia – Director of Economic
Policy at Pfizer Incorporated.